Anti-angiogenic treatment for exudative age-related macular degeneration: New strategies are underway

Current Angiogenesis

Volumn 1, Issue 4, 2012, Pages 318-334

  Nowak Sliwinska, Patrycja ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

Anti angiogenesis; Combination treatment; Endothelium; Exudative age related macular degeneration; Gene therapy; Photodynamic therapy; Tyrosine kinase inhibitors; Vascular endothelial growth factor

Indexed keywords

ADENOVIRUS VECTOR; AFLIBERCEPT; AGANIRSEN; ANGIOGENESIS INHIBITOR; ARC 1905; BEVACIZUMAB; COMBRETASTATIN A4 PHOSPHATE; DEXAMETHASONE; E 10030; ERLOTINIB; PAZOPANIB; PEGAPTANIB; PERCEIVA; PF 04523655; PIGMENT EPITHELIUM DERIVED FACTOR; PLACEBO; POT 4; RANIBIZUMAB; RAPAMYCIN; SIRNA 027; SORAFENIB; SUNITINIB; TARGEGEN; TG 100801; TRIAMCINOLONE ACETONIDE; UNCLASSIFIED DRUG; VATALANIB; VERTEPORFIN; VOLOCIXIMAB;

ANTIANGIOGENIC THERAPY; ARTICLE; CARDIOVASCULAR MORTALITY; CEREBROVASCULAR ACCIDENT; COLORECTAL CANCER; CONJUNCTIVA DISEASE; CONJUNCTIVAL HEMORRHAGE; DISEASE COURSE; DRUG DELIVERY SYSTEM; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; ENDOPHTHALMITIS; EXUDATIVE MACULAR DEGENERATION; EYE PAIN; FALLING; FOLLOW UP; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HUMAN; LASER COAGULATION; MAINTENANCE THERAPY; MONOTHERAPY; MULTICENTER STUDY (TOPIC); NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHOTODYNAMIC THERAPY; PNEUMONIA; POLYPOIDAL CHOROIDAL VASCULOPATHY; PRIORITY JOURNAL; PUNCTATE KERATITIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETINA HEMORRHAGE; RETINA MACULA AGE RELATED DEGENERATION; RETINAL THICKNESS; SIDE EFFECT; SIGNAL TRANSDUCTION; TREATMENT DURATION; VISION; VISUAL ACUITY; VITREOUS FLOATERS; VITREOUS HEMORRHAGE;

EID: 84948094339     PISSN: 22115528     EISSN: 22115536     Source Type: Journal    
DOI: 10.2174/2211552811201040318     Document Type: Article

References (114)

1. Klein R, Klein BE, Linton KL. Prevalence of age-related maculopathy. The Beaver Dam Eye Study. Ophthalmology 1992; 99: 933-43.
2. Au Eong KG. Age-related macular degeneration: an emerging challenge for eye care and public health professionals in the Asia Pacific region. Ann Acad Med 2006; 35: 133-5.
3. Koh A, Lim TH, Au Eong KG, et al. Optimising the management of choroidal neovascularisation in Asian patients: consensus on treatment recommendations for anti-VEGF therapy. Singapore Med J 2011; 52: 232-40.
4. Coppens G, Spielberg L, Leys A. Polypoidal choroidal vasculopathy, diagnosis and management. Bull Soc Belge Ophtalmol 2011; (317): 39-44.
5. Qazi Y, Maddula S, Ambati BK. Mediators of ocular angiogenesis. J Genet 2009; 88: 495-515.
6. Ting AY, Lee TK, MacDonald IM. Genetics of age-related macular degeneration. Curr Opin Ophthalmol 2009; 20: 369-76.
7. Strauss O. The retinal pigment epithelium in visual function. Physiol Rev 2005; 85: 845-81.
8. Barnstable CJ, Tombran-Tink J. Neuroprotective and antiangiogenic actions of PEDF in the eye: molecular targets and therapeutic potential. Prog Retin Eye Res 2004; 23: 561-77.
9. Seddon JM, Reynolds R, Yu Y, Daly MJ, Rosner B. Risk models for progression to advanced age-related macular degeneration using demographic, environmental, genetic, and ocular factors. Ophthalmology 2011; 118: 2203-11.
10. Besharse JC, Pfenninger KH. Membrane assembly in retinal photoreceptors I. Freeze-fracture analysis of cytoplasmic vesicles in relationship to disc assembly. J Cell Biol 1980; 87: 451-63.
11. Schmidt-Erfurth U, Miller J, Sickenberg M, et al. Photodynamic therapy of subfoveal choroidal neovascularization: clinical and angiographic examples. Graefes Arch Clin Exp Ophthalmol 1998; 236: 365-74.
12. Green WR. Histopathology of age-related macular degeneration. Mol Vis 1999; 5: 27.
13. Connolly DT, Heuvelman DM, Nelson R, et al. Tumor vascular permeability factor stimulates endothelial cell growth and angiogenesis. J Clin Invest 1989; 84: 1470-8.
14. van den Bergh H. Photodynamic therapy of age-related macular degeneration: History and principles. Semin Ophthalmol 2001; 16: 181-200.
15. Biarnes M, Mones J, Alonso J, Arias L. Update on geographic atrophy in age-related macular degeneration. Optom Vis Sci 2011; 88: 881-9.
16. Ciardella AP, Donsoff IM, Huang SJ, Costa DL, Yannuzzi LA. Polypoidal choroidal vasculopathy. Surv Ophthalmol 2004; 49: 25-37.
17. Ohno-Matsui K, Morita I, Tombran-Tink J, et al. Novel mechanism for age-related macular degeneration: an equilibrium shift between the angiogenesis factors VEGF and PEDF. J Cell Physiol 2001; 189: 323-33.
18. Laser photocoagulation of subfoveal neovascular lesions in agerelated macular degeneration. Results of a randomized clinical trial. Macular Photocoagulation Study Group. Arch Ophthalmol 1991; 109: 1220-31.
19. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials--TAP report. Treatment of agerelated macular degeneration with photodynamic therapy (TAP) Study Group. Arch Ophthalmol 1999; 117: 1329-45.
20. Bressler NM. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials-tap report 2. Arch Ophthalmol 2001; 119: 198-207.
21. Kaiser PK. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: 5-year results of two randomized clinical trials with an open-label extension: TAP report no. 8. Graefes Arch Clin Exp Ophthalmol 2006; 244: 1132-42.
22. Bressler NM. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization-verteporfin in photodynamic therapy report 2. Am J Ophthalmol 2002; 133: 168-9.
23. Michels S, Hansmann F, Geitzenauer W, Schmidt-Erfurth U. Influence of treatment parameters on selectivity of verteporfin therapy. Invest Ophthalmol Vis Sci 2006; 47: 371-6.
24. Costa RA, Farah ME, Cardillo JA, Calucci D, Williams GA. Immediate indocyanine green angiography and optical coherence tomography evaluation after photodynamic therapy for subfoveal choroidal neovascularization. Retina 2003; 23: 159-65.
25. Weiss A, van den Bergh H, Griffioen AW, Nowak-Sliwinska P. Angiogenesis inhibition for the improvement of photodynamic therapy: the revival of a promising idea. BBA Rev Cancer 2012; 1826: 53-70.
26. Gollnick SO, Evans SS, Baumann H, et al. Role of cytokines in photodynamic therapy-induced local and systemic inflammation. Br J Cancer 2003; 88: 1772-9.
27. Schmidt-Erfurth U, Niemeyer M, Geitzenauer W, Michels S. Time course and morphology of vascular effects associated with photodynamic therapy. Ophthalmology 2005; 112: 2061-9.
28. Rudolf M, Michels S, Schlotzer-Schrehardt U, Schmidt-Erfurth U. Expression of angiogenic factors by photodynamic therapy. Klin Monatsbl Augenheilkd 2004; 221: 1026-32.
29. Zhang X, Jiang F, Zhang ZG, et al. Low-dose photodynamic therapy increases endothelial cell proliferation and VEGF expression in nude mice brain. Lasers Med Sci 2005; 20: 74-9.
30. Schmidt-Erfurth U, Schlotzer-Schrehard U, Cursiefen C, Michels S, Beckendorf A, Naumann GO. Influence of photodynamic therapy on expression of vascular endothelial growth factor (VEGF), VEGF receptor 3, and pigment epithelium-derived factor. Invest Ophthalmol Vis Sci 2003; 44: 4473-80.
31. Grossniklaus HE, Green WR. Choroidal neovascularization. Am J Ophthalmol 2004; 137: 496-503.
32. Hera R, Keramidas M, Peoc'h M, Mouillon M, Romanet JP, Feige JJ. Expression of VEGF and angiopoietins in subfoveal membranes from patients with age-related macular degeneration. Am J Ophthalmol 2005; 139: 589-96.
33. Das A, McGuire PG. Retinal and choroidal angiogenesis: pathophysiology and strategies for inhibition. Prog Retin Eye Res 2003; 22: 721-48.
34. Chakravarthy U, Adamis AP, Cunningham ET, Jr., et al. Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age-related macular degeneration. Ophthalmology 2006; 113: 1508 e1-25.
35. Friberg TR, Tolantino M. Pegaptanib sodium as maintenance therapy in neovascular age-related macular degeneration: the LEVEL study. Br J Ophthalmol 2010; doi:10.1136/bjo.2009.174946.
36. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006; 355: 1419-31.
37. Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006; 355: 1432-44.
38. Regillo CD, Brown DM, Abraham P, et al. Randomized, doublemasked, sham-controlled trial of ranibizumab for neovascular agerelated macular degeneration: PIER Study year 1. Am J Ophthalmol 2008; 145: 239-48.
39. Rosenfeld PJ, Rich RM, Lalwani GA. Ranibizumab: Phase III clinical trial results. Ophthalmol Clin North Am 2006; 19: 361-72.
40. Lalwani GA, Rosenfeld PJ, Fung AE, et al. A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study. Am J Ophthalmol 2009; 148: 43-58 e1.
41. Mulder K, Scarfe A, Chua N, Spratlin J. The role of bevacizumab in colorectal cancer: understanding its benefits and limitations. Expert Opin Biol Ther 2011; 11: 405-13.
42. Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, Jaffe GJ. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 2011; 364: 1897-908.
43. Ziemssen F, Sobolewska B. Therapeutic efficacy of bevacizumab for age-related macular degeneration: what are the implications of CATT for routine management? Drugs Aging 2011; 28: 853-65.
44. Dixon JA, Oliver SC, Olson JL, Mandava N. VEGF Trap-Eye for the treatment of neovascular age-related macular degeneration. Expert Opin Invest Drugs 2009; 18: 1573-80.
45. Nguyen QD, Shah SM, Hafiz G, et al. A phase I trial of an IVadministered vascular endothelial growth factor trap for treatment in patients with choroidal neovascularization due to age-related macular degeneration. Ophthalmology 2006; 113: 1522 e1-e14.
46. Nguyen QD, Hariprasad S, Shah SM. Results of a phase I, doseescalation, safety, tolerability, and bioactivity study of intravitreal VEGF trap in patients with neovascular age-related macular degeneration: the CLEAR-IT I study. Retina Society/Club Jules Gonin Annual Meeting 2006;
47. Heier JS, Boyer D, Nguyen QD, et al. The 1-year results of CLEAR-IT 2, a phase 2 study of vascular endothelial growth factor trap-eye dosed as-needed after 12-week fixed dosing. Ophthalmology 2011; 118: 1098-106.
48. Reference: Available from: http://clinicaltrials.gov/ct2/show/NCT00509795.
49. Reference: Available from: http://clinicaltrials.gov/ct2/show/NCT00637377.
50. Reference: Available from: http://newsroom.regeneron.com/releasedetail.cfm?ReleaseID=629800.
51. Sho K, Takahashi K, Yamada H, et al. Polypoidal choroidal vasculopathy: incidence, demographic features, and clinical characteristics. Arch Ophthalmol 2003; 121: 1392-6.
52. Matsuoka M, Ogata N, Otsuji T, Nishimura T, Takahashi K, Matsumura M. Expression of pigment epithelium derived factor and vascular endothelial growth factor in choroidal neovascular membranes and polypoidal choroidal vasculopathy. Br J Ophthalmol 2004; 88: 809-15.
53. Tsujikawa A, Ooto S, Yamashiro K, Tamura H, Otani A, Yoshimura N. Treatment of polypoidal choroidal vasculopathy by intravitreal injection of bevacizumab. Jpn J Ophthalmol 2010; 54: 310-9.
54. Hikichi T, Ohtsuka H, Higuchi M, et al. Improvement of angiographic findings of polypoidal choroidal vasculopathy after intravitreal injection of ranibizumab monthly for 3 months. Am J Ophthalmol 2010; 150: 674-82 e1.
55. Otani A, Sasahara M, Yodoi Y, et al. Indocyanine green angiography: guided photodynamic therapy for polypoidal choroidal vasculopathy. Am J Ophthalmol 2007; 144: 7-14.
56. Akaza E, Yuzawa M, Matsumoto Y, Kashiwakura S, Fujita K, Mori R. Role of photodynamic therapy in polypoidal choroidal vasculopathy. Jpn J Ophthalmol 2007; 51: 270-7.
57. Chan WM, Lam DS, Lai TY, et al. Photodynamic therapy with verteporfin for symptomatic polypoidal choroidal vasculopathy: one-year results of a prospective case series. Ophthalmology 2004; 111: 1576-84.
58. Gomi F, Ohji M, Sayanagi K, et al. One-year outcomes of photodynamic therapy in age-related macular degeneration and polypoidal choroidal vasculopathy in Japanese patients. Ophthalmology 2008; 115: 141-6.
59. Tsuchiya D, Yamamoto T, Kawasaki R, Yamashita H. Two-year visual outcomes after photodynamic therapy in age-related macular degeneration patients with or without polypoidal choroidal vasculopathy lesions. Retina 2009; 29: 960-5.
60. Akaza E, Mori R, Yuzawa M. Long-term results of photodynamic therapy of polypoidal choroidal vasculopathy. Retina 2008; 28: 717-22.
61. Antoszyk AN, Tuomi L, Chung CY, Singh A. Ranibizumab combined with verteporfin photodynamic therapy in neovascular agerelated macular degeneration (FOCUS): year 2 results. Am J Ophthalmol 2008; 145: 862-74.
62. Schmidt-Erfurth U, Wolf S. Same-day administration of verteporfin and ranibizumab 0.5 mg in patients with choroidal neovascularisation due to age-related macular degeneration. Br J Ophthalmol 2008; 92: 1628-35.
63. Spitzer MS, Ziemssen F, Bartz-Schmidt KU, Gelisken F, Szurman P. Treatment of age-related macular degeneration: focus on ranibizumab. Clin Ophthalmol 2008; 2: 1-14.
64. Cook KM, Figg WD. Angiogenesis inhibitors: current strategies and future prospects. CA Cancer J Clin 2010; 60: 222-43.
65. Couch SM, Bakri SJ. Review of combination therapies for neovascular age-related macular degeneration. Semin Ophthalmol 2011; 26: 114-20.
66. Haines JL, Hauser MA, Schmidt S, et al. Complement factor H variant increases the risk of age-related macular degeneration. Science 2005; 308: 419-21.
67. Frimpong-Boateng A, Bunse A, Rufer F, Roider J. Photodynamic therapy with intravitreal application of triamcinolone acetonide in age-related macular degeneration: functional results in 54 patients. Acta Ophthalmol 2009; 87: 183-7.
68. Hudson HL. The RADICAL Trial: Exploring Combination Therapies. Retina Today 2008; 1: 59-62.
69. Augustin A. Triple therapy for age-related macular degeneration. Retina 2009; 29: S8-11.
70. Yip PP, Woo CF, Tang HH, Ho CK. Triple therapy for neovascular age-related macular degeneration using single-session photodynamic therapy combined with intravitreal bevacizumab and triamcinolone. Br J Ophthalmol 2009; 93: 754-8.
71. Bakri SJ, Couch SM, McCannel CA, Edwards AO. Same-day triple therapy with photodynamic therapy, intravitreal dexamethasone, and bevacizumab in wet age-related macular degeneration. Retina 2009; 29: 573-8.
72. Jo N, Mailhos C, Ju M, et al. Inhibition of platelet-derived growth factor B signaling enhances the efficacy of anti-vascular endothelial growth factor therapy in multiple models of ocular neovascularization. Am J Pathol 2006; 168: 2036-53.
73. Helfrich I, Scheffrahn I, Bartling S, et al. Resistance to antiangiogenic therapy is directed by vascular phenotype, vessel stabilization, and maturation in malignant melanoma. J Exp Med 2010; 207: 491-503.
74. Available from: Reference: Available from: http://clinicaltrials.gov/ct2/show/NCT00569140.
75. Available from: http://clinicaltrials.gov/ct2/show/NCT01089517.
76. Doukas J, Mahesh S, Umeda N, et al. Topical administration of a multi-targeted kinase inhibitor suppresses choroidal neovascularization and retinal edema. J Cell Physiol 2008; 216: 29-37.
77. Nowak-Sliwinska P, Weiss A, van Beijnum JR, et al. Angiostatic kinase inhibitors to sustain photodynamic angio-occlusion. J Cell Mol Med 2012; 16: 1553-62.
78. Barakat MR, Kaiser PK. VEGF inhibitors for the treatment of neovascular age-related macular degeneration. Expert Opin Investig Drugs 2009; 18: 637-46.
79. Reference: Available from: http://clinicaltrials.gov/ct2/show/NCT01134055.
80. Reference: Available from: http://clinicaltrials.gov/ct2/show/NCT00138632.
81. Campa C, Harding SP. Anti-VEGF compounds in the treatment of neovascular age related macular degeneration. Curr Drug Targets 2011; 12: 173-81.
82. Barik S. Development of gene-specific double-stranded RNA drugs. Ann Med 2004; 36: 540-51.
83. Castanotto D, Rossi JJ. The promises and pitfalls of RNAinterference-based therapeutics. Nature 2009; 457: 426-33.
84. Kaiser PK, Symons RC, Shah SM, et al. RNAi-based treatment for neovascular age-related macular degeneration by Sirna-027. Am J Ophthalmol 2010; 150: 33-9 e2.
85. Reference: Available from: http://www.clinicaltrials.gov/ct2/show/NCT00713518.
86. Reference: Available from: http://www.clinicaltrials.gov/ct2/show/NCT00709527.
87. Reference: Available from: http://clinicaltrials.gov/ct2/show/NCT00473928.
88. Sabatini DM. mTOR and cancer: insights into a complex relationship. Nat Rev Cancer 2006; 6: 729-34.
89. Reference: Available from: http://www.clinicaltrials.gov/ct2/show/NCT00766337.
90. Van Vliet KM, Blouin V, Brument N, Agbandje-McKenna M, Snyder RO. The role of the adeno-associated virus capsid in gene transfer. Methods Mol Biol 2008; 437: 51-91.
91. McVey D, Hamilton MM, Hsu C, King CR, Brough DE, Wei LL. Repeat administration of proteins to the eye with a single intraocular injection of an adenovirus vector. Mol Ther 2008; 16: 1444-9.
92. Guo ZS, Wang LH, Eisensmith RC, Woo SL. Evaluation of promoter strength for hepatic gene expression in vivo following adenovirus-mediated gene transfer. Gene Ther 1996; 3: 802-10.
93. Campochiaro PA, Nguyen QD, Shah SM, et al. Adenoviral vectordelivered pigment epithelium-derived factor for neovascular agerelated macular degeneration: results of a phase I clinical trial. Hum Gene Ther 2006; 17: 167-76.
94. Maclachlan TK, Lukason M, Collins M, et al. Preclinical safety evaluation of AAV2-sFLT01-a gene therapy for age-related macular degeneration. Mol Ther 2011; 19: 326-34.
95. Available from: http://clinicaltrials.gov/ct2/show/NCT01024998.
96. Available from: http://clinicaltrials.gov/ct2/show/NCT01301443.
97. McKeage MJ, Baguley BC. Disrupting established tumor blood vessels: an emerging therapeutic strategy for cancer. Cancer 2010; 116: 1859-71.
98. Nambu H, Nambu R, Melia M, Campochiaro PA. Combretastatin A-4 phosphate suppresses development and induces regression of choroidal neovascularization. Invest Ophthalmol Vis Sci 2003; 44: 3650-5.
99. Ni Z, Hui P. Emerging pharmacologic therapies for wet age-related macular degeneration. Ophthalmologica 2009; 223: 401-10.
100. Reference: Available from: http://www.globenewswire.com/newsroom/news.html?d=240145.
101. Umeda S, Suzuki MT, Okamoto H, et al. Molecular composition of drusen and possible involvement of anti-retinal autoimmunity in two different forms of macular degeneration in cynomolgus monkey (Macaca fascicularis). FASEB J 2005; 19: 1683-5.
102. Available from: http://clinicaltrials.gov/ct2/show/NCT00782093.
103. Jiang ZY, He Z, King BL, et al. Characterization of multiple signaling pathways of insulin in the regulation of vascular endothelial growth factor expression in vascular cells and angiogenesis. J Biol Chem 2003; 278: 31964-71.
104. Andrieu-Soler C, Berdugo M, Doat M, Courtois Y, BenEzra D, Behar-Cohen F. Downregulation of IRS-1 expression causes inhibition of corneal angiogenesis. Invest Ophthalmol Vis Sci 2005; 46: 4072-8.
105. White MF. The IRS-signaling system: a network of docking proteins that mediate insulin and cytokine action. Recent Prog Horm Res 1998; 53: 119-38.
106. Al-Mahmood S, Colin S, Farhat N, Thorin E, Steverlynck C, Chemtob S. Potent in vivo antiangiogenic effects of GS-101 (5'-TATCCGGAGGGCTCGCCATGCTGCT-3'), an antisense oligonucleotide preventing the expression of insulin receptor substrate-1. J Pharmacol Exp Ther 2009; 329: 496-504.
107. Cloutier F, Lawrence M, Goody R, et al. Anti-angiogenic activity of Aganirsen in non-human primate and rodent models of retinal neovascular disease following topical administration. Invest Ophthalmol Vis Sci 2012; 53: 1195-203.
108. Nowak-Sliwinska P, Storto M, Cataudella T, et al Angiogenesis inhibition by the maleimide-based small molecule GNX-686. Microvas Res 2012; 83: 105-10.
109. Sieving PA, Caruso RC, Tao W, et al. Ciliary neurotrophic factor (CNTF) for human retinal degeneration: phase I trial of CNTF delivered by encapsulated cell intraocular implants. Proc Natl Acad Sci U S A 2006; 103: 3896-901.
110. Singh SR, Grossniklaus HE, Kang SJ, Edelhauser HF, Ambati BK, Kompella UB. Intravenous transferrin, RGD peptide and dualtargeted nanoparticles enhance anti-VEGF intraceptor gene delivery to laser-induced CNV. Gene Ther 2009; 16: 645-59.
111. Verheul HM, Pinedo HM. Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition. Nat Rev Cancer 2007; 7: 475-85.
112. Ebos JM, Lee CR, Cruz-Munoz W, Bjarnason GA, Christensen JG, Kerbel RS. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 2009; 15: 232-9.
113. Yasukawa T, Ogura Y, Kimura H, Sakurai E, Tabata Y. Drug delivery from ocular implants. Expert Opin Drug Deliv 2006; 3: 261-73.
114. van Beijnum JR, Nowak-Sliwinska P, van den Boezem E, Hautvast P, Buurman W, Griffioen A. Tumor angiogenesis is enforced by autocrine regulation of high-mobility group box 1. Oncogene 2012; 1: 1-12.